公开(公告)号：US20070293901A1

公开(公告)日：2007-12-20

申请号：US11802685

申请日：2007-05-24

申请人： Benny Rousso ,  Hani Sabbah

发明人： Benny Rousso ,  Hani Sabbah

IPC分类号： A61N1/00

CPC分类号： A61N1/3621 ,  A61N1/3627

摘要： A method of treating a cardiac arrhythmia, comprising: determining a desired arrhythmia control; selecting an electric field having an expected effect of modifying protein activity of at least one protein as a response of a cardiac tissue to the field, said expected effect correlated with said desired arrhythmia control; and applying said field to said cardiac tissue.

摘要翻译： 一种治疗心律失常的方法，包括：确定所需的心律失常对照; 选择具有将至少一种蛋白质的蛋白质活性改变为心脏组织的应答的预期效果的电场，所述预期效果与所述期望的心律失常控制相关; 以及将所述场应用于所述心脏组织。

公开(公告)号：US20070027487A1

公开(公告)日：2007-02-01

申请号：US10549216

申请日：2004-03-10

申请人： Yuval Mika ,  Hani Sabbah ,  Walid Haddad ,  Benny Rousso

发明人： Yuval Mika ,  Hani Sabbah ,  Walid Haddad ,  Benny Rousso

IPC分类号： A61N1/00

CPC分类号： A61N1/0587 ,  A61N1/326 ,  A61N1/362 ,  A61N1/3627 ,  A61N1/36557

摘要： Method and apparatus (120) for modifying gene expression in cardiac muscle cells (110), by the application of electric fields.

摘要翻译： 用于通过施加电场来修饰心肌细胞（110）中的基因表达的方法和装置（120）。

公开(公告)号：US20120041393A1

公开(公告)日：2012-02-16

申请号：US13119173

申请日：2009-09-04

申请人： Frank Ahmann ,  Hani Sabbah ,  Donald Shannon

发明人： Frank Ahmann ,  Hani Sabbah ,  Donald Shannon

IPC分类号： A61M5/32

CPC分类号： A61M25/1029 ,  A61B17/7097 ,  A61B2090/3966 ,  A61F2/0059 ,  A61F2/12 ,  A61F5/0036 ,  A61L31/04 ,  A61L31/14 ,  A61L31/146 ,  A61M25/1027 ,  A61M2025/0089 ,  A61M2025/1054

摘要： Capsules, emplacement apparatus, and associated methods for establishing a capsule within tissue are described herein. The emplacement apparatus may be catheter-based or implemented in a handheld unit. The emplacement apparatus serves to introduced an encapsulating membrane in a collapsed condition into the tissue, and then to expand the encapsulating membrane within the tissue into a capsule by injection of fill material into the encapsulating membrane. Other than being capable of injection through the emplacement apparatus, the fill material may be selected and formulated to achieve such mechanical and biological properties within the encapsulating membrane after injection as are desired to achieve the therapeutic effect sought for the patient. Mechanically, the fill material within the encapsulating membrane after injection may be a liquid, a semi-solid such as a gel, or a solid such as a cross-linked polymer. The fill material may or may not be sealed within the encapsulating membrane.

摘要翻译： 本文描述了用于在组织内建立胶囊的胶囊，置换装置和相关方法。 移植装置可以是基于导管的或在手持单元中实现的。 放置装置用于将处于折叠状态的封装膜引入组织中，然后通过将填充材料注入到包封膜中将包封膜在组织内膨胀成胶囊。 除了能够通过放置装置注射之外，可以选择和配制填充材料以在注射之后在包封膜内实现如实现对患者所寻求的治疗效果所希望的这样的机械和生物学特性。 在机械上，注射后的包封膜内的填充材料可以是液体，半固体如凝胶，或诸如交联聚合物的固体。 填充材料可以或可以不被密封在封装膜内。

公开(公告)号：US20080065048A1

公开(公告)日：2008-03-13

申请号：US11900005

申请日：2007-09-07

申请人： Hani Sabbah ,  Randall Lee ,  Andrew Hinson

发明人： Hani Sabbah ,  Randall Lee ,  Andrew Hinson

IPC分类号： A61M31/00

CPC分类号： A61F2/2451 ,  A61F2/2481 ,  A61F2002/249 ,  A61F2250/0067 ,  A61K9/0024 ,  A61L27/20 ,  A61L27/3873 ,  A61L27/52 ,  A61L2400/06 ,  A61M5/14 ,  A61M5/178 ,  A61M37/00 ,  A61M37/0069

摘要： Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

公开(公告)号：US20050004428A1

公开(公告)日：2005-01-06

申请号：US10839724

申请日：2004-05-04

申请人： James Cox ,  Michael Girard ,  Donald Palme ,  Donald Rohrbaugh ,  Hani Sabbah ,  J. Shapland ,  Robert Walsh

发明人： James Cox ,  Michael Girard ,  Donald Palme ,  Donald Rohrbaugh ,  Hani Sabbah ,  J. Shapland ,  Robert Walsh

IPC分类号： A61K45/00 ,  A61F2/00 ,  A61F2/02 ,  A61K35/12 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06

CPC分类号： A61F2/2481 ,  D04B21/12 ,  D10B2509/08 ,  Y10S977/907

摘要： A device for treating cardiac disease of a heart having an upper portion and a lower portion divided by an A-V groove, the device including a jacket adapted to be secured to the heart, and a non-adherent material in association with the jacket. The jacket is fabricated from a flexible material defining a volume between an upper and a lower end, the jacket being adapted to be adjusted on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain expansion of the heart beyond the maximum adjusted volume during diastole and permit substantially unimpeded contraction of the heart during systole. As a result of the flexible material, the jacket allows unimpeded diastolic filling of the heart. Also described is a method for treating cardiac disease including surgically accessing the heart, applying the treatment device of the invention, securing the treatment device to the heart, and surgically closing access to the heart while leaving the treatment device on the heart.

摘要翻译： 一种用于治疗心脏的心脏疾病的装置，其具有由A-V凹槽分隔的上部和下部，所述装置包括适于固定到心脏的护套以及与护套相关联的非粘附材料。 护套由限定上下端之间的体积的柔性材料制成，护套适于在心脏上调节以紧密地符合心脏的外部几何形状，并且假设用于护套约束的最大调节体积 舒张期心脏扩张超出最大调节体积，并允许心脏在收缩期间基本无阻碍地收缩心脏。 作为柔性材料的结果，护套可以无阻碍地舒张心脏填充心脏。 还描述了一种治疗心脏疾病的方法，包括手术进入心脏，施用本发明的治疗装置，将治疗装置固定到心脏，以及在将治疗装置留在心脏上时手术闭合进入心脏。

公开(公告)号：US20090176772A1

公开(公告)日：2009-07-09

申请号：US12393952

申请日：2009-02-26

申请人： Brent Blackburn ,  Hani Sabbah

发明人： Brent Blackburn ,  Hani Sabbah

IPC分类号： A61K31/5415 ,  A61K31/495 ,  A61P9/00

CPC分类号： A61K45/06 ,  A61K31/495 ,  A61K2300/00

摘要： The present invention relates to method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

摘要翻译： 本发明涉及通过联合施用治疗有效量的雷洛嗪和至少一种共重塑剂（其可以是ACE抑制剂，ARB或β-阻断剂）逆转左心室重塑的方法。 该方法可用于治疗心力衰竭。 本发明还涉及适合于这种组合给药的药物制剂。

公开(公告)号：US20080065047A1

公开(公告)日：2008-03-13

申请号：US11899963

申请日：2007-09-07

申请人： Hani Sabbah ,  Randall Lee ,  Andrew Hinson

发明人： Hani Sabbah ,  Randall Lee ,  Andrew Hinson

IPC分类号： A61M31/00

CPC分类号： A61F2/2451 ,  A61F2/2481 ,  A61F2002/249 ,  A61F2250/0067 ,  A61K9/0024 ,  A61L27/20 ,  A61L27/3873 ,  A61L27/52 ,  A61L2400/06 ,  A61M5/14 ,  A61M5/178 ,  A61M37/00 ,  A61M37/0069

摘要： Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

摘要翻译： 心肌病可以通过以围绕心脏的一个或多个腔室的模式在心肌内分布空间占位剂来治疗，使得空间改变剂整合到腔室周围的至少部分心脏壁并使其增厚， 降低壁面应力，稳定或甚至减小腔室尺寸。 一些模式也引起了对室的有益的全局整形。 这些变化迅速发生并且是可持续的，并且对心脏功能具有快速和可持续的治疗作用。 随着时间的推移，墙壁压力的减轻会降低氧气消耗并促进愈合。 此外，根据空间占据剂的特性，包括与其它治疗材料的组合，可以实现各种长期治疗效果。 可通过这些系统和方法治疗的特异性心脏病症包括例如扩张型心肌病（有或没有明显的动脉瘤形成），充血性心力衰竭和室性心律失常。 用于全局调整大小的心肌内的空间占位剂的分布模式也可以被使用或增加以治疗局部的情况，例如心肌梗死，通常形成响应于大的透壁性心肌梗死的心室壁的明显的动脉瘤和二尖瓣反流 到不合规的二尖瓣。 这些技术也可用于治疗可能尚未进展为心肌病的局部病症。

公开(公告)号：US20080065046A1

公开(公告)日：2008-03-13

申请号：US11899962

申请日：2007-09-07

申请人： Hani Sabbah ,  Randall Lee ,  Andrew Hinson

发明人： Hani Sabbah ,  Randall Lee ,  Andrew Hinson

IPC分类号： A61M31/00

CPC分类号： A61F2/2451 ,  A61F2/2481 ,  A61F2002/249 ,  A61F2250/0067 ,  A61K9/0024 ,  A61L27/20 ,  A61L27/3873 ,  A61L27/52 ,  A61L2400/06 ,  A61M5/14 ,  A61M5/178 ,  A61M37/00 ,  A61M37/0069

摘要： Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

摘要翻译： 心肌病可以通过以围绕心脏的一个或多个腔室的模式在心肌内分布空间占位剂来治疗，使得空间改变剂整合到腔室周围的至少部分心脏壁并使其增厚， 降低壁面应力，稳定或甚至减小腔室尺寸。 一些模式也引起了对室的有益的全局整形。 这些变化迅速发生并且是可持续的，并且对心脏功能具有快速和可持续的治疗作用。 随着时间的推移，墙壁压力的减轻会降低氧气消耗并促进愈合。 此外，根据空间占据剂的特性，包括与其它治疗材料的组合，可以实现各种长期治疗效果。 可通过这些系统和方法治疗的特异性心脏病症包括例如扩张型心肌病（有或没有明显的动脉瘤形成），充血性心力衰竭和室性心律失常。 用于全局调整大小的心肌内空间占位剂的分布模式也可以被使用或增加以治疗局部的情况，例如心肌梗死，通常形成为响应于大的透壁性心肌梗死的室壁的明显的动脉瘤和二尖瓣反流 到不合规的二尖瓣。 这些技术也可用于治疗可能尚未进展为心肌病的局部病症。

公开(公告)号：US20060111361A1

公开(公告)日：2006-05-25

申请号：US11271168

申请日：2005-11-09

申请人： Brent Blackburn ,  Hani Sabbah

发明人： Brent Blackburn ,  Hani Sabbah

IPC分类号： A61K31/495 ,  A61K31/47 ,  A61K31/4184 ,  A61K31/403 ,  A61K31/401 ,  A61K31/138

CPC分类号： A61K45/06 ,  A61K31/495 ,  A61K2300/00

摘要： The present invention relates to method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

摘要翻译： 本发明涉及通过联合施用治疗有效量的雷洛嗪和至少一种共重塑剂（其可以是ACE抑制剂，ARB或β-阻断剂）逆转左心室重塑的方法。 该方法可用于治疗心力衰竭。 本发明还涉及适合于这种组合给药的药物制剂。